Relief Therapeutics Announces In-Licensing Agreement to Develop and Commercialize Atexakin Alfa For the Treatment of Peripheral Neuropathies
Relief Therapeutics a Swiss-based, privately owned startup company announced today an in-licensing agreement from Merck Serono, the biopharmaceutical business of Merck, Darmstadt, Germany, giving Relief Therapeutics the worldwide exclusive rights to develop and commercialize atexakin alfa. Financial terms were not disclosed.
Under the terms of the agreement, Relief Therapeutics will develop atexakin alfa for the treatment of neuropathies. Atexakin alfa has the potential of relieving pain, as well as non-pain symptoms associated with neuropathies by restoring normal innervation in the periphery.
“This agreement constitutes a great opportunity to develop the first disease modifying treatment that has the potential to significantly reduce the burden of neuropathies to patients, care givers and society,” said Dr. Gael Hédou, co-founder of Relief Therapeutics.
About Atexakin alfa
Atexakin alfa is a human recombinant version of interleukin-6 that has shown in preclinical studies to induce the re-growth of nerves and to re-establish normal nerve conduction and sensory perception in various relevant animal models of neuropathies. Initially discovered at the Weizmann institute (IL), this molecule was first tested as a potential treatment for thrombocytopenia in chemotherapy-treated cancer patients allowing the delineation of its safety and pharmacodynamic profiles. Based on positive preclinical, toxicological and clinical data obtained at this time, Relief Therapeutics will engage into clinical development to test the therapeutic efficacy of atexakin alfa in diabetic patients suffering from neuropathy.
About Peripheral Neuropathies
Peripheral neuropathies are a group of conditions characterized by degeneration of peripheral motor, sensory, or autonomic nerves. Degeneration of peripheral nerves causes a wide variety of symptoms and signs ranging from intractable pain, numbness and tingling to potentially impairment of strength, balance, and coordination. Neuropathies develop as a result of toxic, inflammatory, infectious, genetic, neoplastic, and metabolic diseases. Medications, particularly chemotherapy are also a common cause. In the case of diabetic neuropathy, half of the diabetic population worldwide becomes affected during the course of their disease. Quality of life is heavily affected in patients with neuropathy and the costs associated with medical care and lost wages is substantial. There are very few therapies available to patients suffering from these disorders and treatments are often associated with side effects limiting their use. Furthermore, no treatment truly stops or reverses neuropathy. Atexakin alfa has the potential to restore nerve function and potentially alleviate painful and non-pain-related symptoms.
About Relief Therapeutics
Relief Therapeutics is a privately owned startup company based in Geneva, Switzerland, incorporated in 2013. Relief Therapeutics is committed to develop new treatments for diseases with high unmet needs and significant burden on patients’ quality of life and society.
This news release contains forward-looking statements that are subject to known and unknown risks and uncertainties causing results to potentially differ from the statements made. Relief Therapeutics and Merck Serono cannot be taken responsible in any manner if such statements are not verified in the future.
Dr. Gael Hédou
tel:+41 79 457 0937
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
HCL Technologies Powers Volvo Ocean Race 2017-1823.10.2017 13:02 | Pressemelding
The 2017-18 edition of the Volvo Ocean Race was flagged off at Alicante, Spain, with HCL Technologies as the strategic IT services provider. The leading global IT services company has provided end-to-end infrastructure support as well as connectivity between the Race Village and the Command Centre in Alicante further connecting them to 12 Host Cities on the race route globally. The world's longest and toughest professional sporting event began at Alicante and will finish eight months later at The Hague. At the flag-off, Jordi Neves, Chief Digital Officer, Volvo Ocean Race, said: “Over four decades, Volvo Ocean Race has drawn some of the greatest ever sailors. This edition of the race will be more digitally focused than before, with HCL as the strategic IT services provider. This edition is also special for us as we embark on a major Sustainability Program in partnership wi
CES Unveiled Paris Returns Tomorrow for Fifth Year with 70+ Exhibitors23.10.2017 13:00 | Pressemelding
Consumer Technology Association (CTA): WHAT: CES Unveiled Paris returns to Paris tomorrow, for its fifth consecutive year, hosting more than 70 exhibitors. More than 600 attendees are expected at the event which will unite French tech startups, top media, buyers and industry influencers around the latest tech innovation and provide a preview of CES® 2018. Schedule as follows:
Wipro Cited as a Leader in Everest Group PEAK Matrix™ for IT Security Services23.10.2017 12:59 | Pressemelding
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been recognized as a ‘Leader’ by Everest Group, a global independent consulting and research firm, in its report titled “IT Security Services- Market Trends and PEAK MatrixTM Assessment 2017: Security- the Biggest Digital Insecurity”. The report analyzed the capabilities of 17 leading global IT service providers on Everest Group’s PEAK Matrix. Wipro has been named as a Leader for its strong global delivery network with a transformational mind-set, and its ability to deliver high quality of services across regions and service segments, in terms of both execution and responsiveness. The report highlights the trends influencing the IT security services market, focusing on the increasing complexities, size and
ZeroStack Delivers Unified Multi-Cloud Application Development Platform Leveraging Existing Hardware Assets23.10.2017 12:00 | Pressemelding
ZeroStack, Inc., creators of the self-driving on-premises cloud, today announced that its cloud platform now runs on Nutanix HCI hardware, expanding choices for IT departments that want to empower their DevOps groups with a software-defined infrastructure that offers SaaS-delivered, multi-cloud operations. Developers can have a consistent platform no matter where they are located while reducing operational complexity and costs. Developers need a common platform to reduce costs and ensure efficient processes for software development, and budget-constrained IT departments want to gain maximum leverage out of existing hardware. ZeroStack’s Intelligent Cloud Platform is hardware independent, so it enables consistent processes regardless of the hardware used or where the developers access the infrastructure. As a result, developers can create secure private workspaces and build a per
Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab23.10.2017 11:15 | Pressemelding
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that the companies have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171023005462/en/ Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta (Aβ) antibody for patients with Alzheimer’s disease (“AD”). The expanded agreement leverages each company’s respective geographic strengths for commercialization and adjusts the respective share of profits from potential sales of aducanumab. Biogen will receive 55
Open Letter from Mats Granryd, Director General, GSMA23.10.2017 11:01 | Pressemelding
Dear Ministers, As you are no doubt aware, European citizens and businesses rely on mobile networks to socialise, do business and access information everyday in every corner of every Member State of the Union. The social and economic activity that rides over this digital infrastructure drives economic growth, shapes future innovation and fosters more inclusive societies. As you prepare to convene at tomorrow’s Ministerial Council Meeting, I must express my grave concerns on the current state of discussions on the proposed European Electronic Communication Code (the Code). Although the European Union’s vision of a ‘Gigabit Society’, and recent discussions amongst the European Heads of State, demonstrate a strong ambition to recapture the region’s digital leadership and harness the full power of digital to drive growth, jobs and competitiveness, we do not see action foc
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom